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Abstract 
Purpose 
To evaluate final-year pharmacy students’ perceptions toward pharmacogenomics education, their 
attitudes on its clinical relevance, and their readiness to use such knowledge in practice. 
Methods 
A 19-question survey was developed and modified from prior studies and was pretested on a small group 
of pharmacogenomics faculty and pharmacy students. The final survey was administered to 978 final-
year pharmacy students in 8 school/colleges of pharmacy in New York and New Jersey between January 
and May 2017. The survey targeted 3 main themes: perceptions toward pharmacogenomics education, 
attitudes toward the clinical relevance of this education, and the students’ readiness to use knowledge of 
pharmacogenomics in practice. 
Results 
With a 35% response rate, the majority (81%) of the 339 student participants believed that 
pharmacogenomics was a useful clinical tool for pharmacists, yet only 40% felt that it had been a relevant 
part of their training. Almost half (46%) received only 1–3 lectures on pharmacogenomics and the 
majority were not ready to use it in practice. Survey results pointed toward practice-based trainings such 
as pharmacogenomics rotations as the most helpful in preparing students for practice. 
Conclusions 
Final-year student pharmacists reported varying exposure to pharmacogenomics content in their 
pharmacy training and had positive attitudes toward the clinical relevance of the discipline, yet they 
expressed low confidence in their readiness to use this information in practice. 
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Abstract: 
Purpose: To evaluate final year pharmacy students’ perceptions towards pharmacogenomics 
education; their attitudes on its clinical relevance; and their readiness to use such knowledge in 
practice. 
Methods: A 19-question survey was developed and modified from prior studies and was 
pretested on a small group of pharmacogenomics faculty and pharmacy students.  The final 
survey was administered to 978 final year pharmacy students in eight school/colleges of 
pharmacy in New York and New Jersey between January and May 2017. The survey targeted 
three main themes: perceptions toward pharmacogenomics education, attitudes towards the 
clinical relevance of this education and the students’ readiness to use knowledge of 
pharmacogenomics in practice.  
Results: With a 35% response rate, the majority (81%) of the 339 students participants believed 
that pharmacogenomics is a useful clinical tool for pharmacists yet only 40% felt that it had been 
a relevant part of their training. Almost half (46%) received only 1 – 3 lectures on 
pharmacogenomics and the majority are not ready to use it in practice. Survey results pointed 
towards practice-based trainings such as pharmacogenomics rotations as the most helpful in 
preparing students for practice.  
Conclusions: Most of the final year student pharmacists had some exposure to 
pharmacogenomics content in their training and positive attitudes towards the clinical relevance 
of the discipline; however an overwhelming majority expressed low confidence in their readiness 
to utilize this information in practice. Hence, practice-based training opportunities taught by 
well-trained faculty may be needed to prepare future pharmacists in this discipline.  
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Introduction  
Pharmacogenomics is the study of how an individual’s genome can influence his or her 
response to drugs.(1) To date, over 200 FDA-approved medications have pharmacogenomics 
product-label changes and polymorphisms in genes that encode drug-metabolizing enzymes 
make up 80% of these product label updates.(2)   However, widespread adoption into clinical 
practice has been lagging behind the technological advances and research discoveries.  
For decades, pharmacists have played pivotal roles in health care to optimize drug 
therapy while minimizing and/or preventing adverse drug events. Pharmacists’ extensive 
knowledge of pharmacotherapy and their skillsets in therapy optimization uniquely positions 
them to assume key functions and leadership in the clinical implementation of 
pharmacogenomics.(3) The 2015 American Society of Health-System Pharmacists (ASHP) 
statement on the Pharmacist’s Role in Clinical Pharmacogenomics not only affirmed the 
esteemed professional society’s support of pharmacogenomics but it also highlighted five 
responsibilities of pharmacists in this specialty. Advocating for the rational and routine use of 
pharmacogenomics testing, providing test results interpretation; and educating providers and 
patients on clinical application of pharmacogenomics are few of the aforementioned roles of 
pharmacists.(4)  
  In a survey of 303 pharmacists, 65% believed that pharmacists need to be knowledgeable 
about the appropriate use of pharmacogenomics testing however, nearly the same number of 
respondents felt inadequately prepared to use the results of pharmacogenomics tests in 
practice.(5) This sentiment has been reported by others as well.(6-9) Reports in 2005 
demonstrated that only 39% of pharmacy schools included pharmacogenomics content in their 
curricula.(10) Fast forward to 2010,  and Murphy et al reported an impressive improvement with 
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90% of schools reporting curricula adoption of pharmacogenomics content.(11) In the Murphy 
report, the authors also reported varying degrees of content coverage among the schools and 
more than half had no plans for faculty development in pharmacogenomics.(11)  
The marked increase in the number of pharmacy schools with pharmacogenomics 
training may be attributed to the efforts of the Accreditation Council for Pharmacy Education 
(ACPE) and the American Association of Colleges of Pharmacy (AACP) since the 2005 report. 
The ACPE issued pharmacogenomics content requirements for all pharmacy schools effective 
July 2007.(12) Moreover, the 2008 AACP House of Delegates approved resolutions that called 
for training and curricula modifications to address implications of personalized medicine and 
biotechnology as well as tailored faculty training in these disciplines.(13)  
It has been a decade since the initial recommendation to focus on pharmacogenomics 
training in our schools of pharmacy and as such we sought to investigate how the educational 
strategies and increased training have affected the newly graduating pharmacists. The objective 
of this study was to assess 2017 final year pharmacy students’ perceptions and attitudes on 
pharmacogenomics and their readiness to incorporate it into their practice as pharmacists.  
 
Methods 
Survey Participants 
All eleven schools/colleges of pharmacy in New York, New Jersey and Connecticut were invited 
however three schools did not respond and were therefore excluded from the study. The eight 
schools that participated are Albany College of Pharmacy and Health Sciences, Touro College of 
Pharmacy, St. John Fisher College Wegmans School of Pharmacy, D’Youville College School of 
Pharmacy, Fairleigh Dickinson University, St. John’s University, Long Island University Arnold 
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& Marie Schwartz College of Pharmacy
 
and University at Buffalo School of Pharmacy and 
Pharmaceutical Sciences. The appropriate Human Subjects Protection Program Institutional 
Review Board approvals were granted to all participating schools. In all, 978 final year students 
(Class of 2017) were eligible to participate in the survey. 
 
 
Design 
This was a descriptive study that employed a 19-question survey developed and modified 
from prior studies (11, 14) to assess participant demographics and three main themes: (1) the 
students’ attitudes towards pharmacogenomics education; (2) their perceptions on the clinical 
relevance of pharmacogenomics; and (3) their readiness to adopt it into their practice. A five-
point likert-scale ranging from strongly agree to strongly disagree was used to score the 
responses. A pretest of the survey tool was conducted with four academic pharmacists involved 
in pharmacogenomics research and didactic training as well as three pharmacy students 
undergoing pharmacogenomics advanced pharmacy practice experiential (APPE) rotation. All 
“pre-testers” provided feedback on content, length, clarity and utility of the survey tool which 
was then used to refine the final set of questions. Additionally, the authors reviewed and 
approved the questionnaire before it was administered. The survey was administered 
electronically via www.surveymonkey.com between January and May 2017 and faculty-student 
champions from each of the participating schools deployed the link to the questionnaire to the 
graduating class of their respective schools. The participants were given 8 weeks to complete the 
survey initially. After that, the deadline for completion was extended for an additional four 
weeks.  Two reminder emails were sent by the faculty-student champions in four week intervals. 
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Moreover, the faculty champions provided additional information on their respective schools and 
the nature of the PGx courses offered.  
Statistical Analysis 
Survey data was collected using surveymonkey.com and interpreted using a range of 
descriptive statistical methods, such as cross-tabulations, comparisons of means and standard 
deviations across multinomial variables, and data visualization. Ordinal logistic regression was 
used to estimate the overall main effects of certain demographic predictors, which were 
converted to ordered categorical variables, on the survey response outcomes. All statistical 
analyses were conducted in SPSS 23 and R.  
 
Results  
Student Demographics 
Of 978 students eligible for the study, 339 (35%) students completed the survey. Table 1 
summarizes the relevant demographics. The respondents were mostly females (n= 213, 63%). A 
majority were between the ages of 21 and 25, (n=194, 57%) and 26 and 30 years (n =106, 31%). 
High school was the most common educational level completed by the respondents prior to 
matriculating to pharmacy school as reported by 147 (43%) students and 158 (47%)  plan to 
pursue community pharmacy opportunities post-graduation.  
Description of the Pharmacogenomics Educational Opportunities at the Participating Schools 
 As shown in Table 2, pharmacogenomics is integrated through other courses at two 
schools; offered as a standalone course in four schools and as both integrated and standalone in 
the remaining two schools of pharmacy. Of those with standalone courses, four require it for all 
their students and two offer it as an elective class. Notably, only two PGx faculty members have 
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been formally trained in pharmacogenomics, while others have undergone varying degrees of 
training. The learning objectives differ across schools and an elective PGx APPE rotation is 
available to students from three of the participating schools.  
Exposure to pharmacogenomics education 
The respondents were queried on their exposure to pharmacogenomics content in their 
pharmacy school curricula (Figure 1). One hundred and fifty-six (46%) were exposed to 1 – 3 
pharmacogenomics lectures, 96 (28%) completed a required pharmacogenomics course, 20 (6%) 
took an elective pharmacogenomics course, 8 (2%) completed a pharmacogenomics APPE 
rotation, 39 (12%) did not receive any pharmacogenomics training and 19 (6%) did not respond 
to this question.  
Perception on the Clinical Relevance of Pharmacogenomics 
Four questions were posed to investigate the perceived clinical utility and relevance of 
pharmacogenomics among the final year student pharmacists (Table 3). Majority (81%, n=273) 
believed that pharmacogenomics is a useful tool that pharmacists and medical professionals can 
use to optimize medication efficacy and/or prevent adverse events and more than half (63%, 
n=234) affirmed that it is an integral part of the pharmacy profession. Sixty-one percent (n=205) 
perceived that pharmacogenomics may be an integral part of their practice as pharmacists and 
slightly more (69%, n=234) predicted that they may encounter pharmacogenomics-related 
questions during their practice as pharmacists.  
Attitudes towards pharmacogenomics education 
Approximately seventy-one percent (n = 239) of the respondents believe that 
pharmacogenomics should be covered in detail in all schools and colleges of pharmacy; 
however, only 40% (n=136) felt that it had been a relevant part of their Doctor of Pharmacy 
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curriculum. Moreover, 51% (n=175) agreed that final year pharmacy students should be required 
to have substantial knowledge of pharmacogenomics prior to graduation and 56% (n=188) 
indicated their intentions of reading pharmacogenomics-related literature post-graduation 
especially those that pertain to their respective practices and specialties (Table 2).  
The students’ past exposure to pharmacogenomics training content was significantly 
associated with their attitudes towards pharmacogenomics education. Pharmacogenomics 
training (Figure 1) was converted into an ordered categorical variable, with the lowest level 
being no exposure to pharmacogenomics in pharmacy school (n = 39), followed by 1-3 lectures 
or seminars (n=156), elective pharmacogenomics course (n=20), required pharmacogenomics 
course (n=96), and finally the highest level being pharmacogenomics APPE rotation (n= 8). This 
measure of pharmacogenomics training was significantly associated with more agreement to 
three of the four questions assessing attitudes towards pharmacogenomics education (Figure 2).  
Readiness to Use Pharmacogenomics Knowledge in Practice 
As proposed by the ASHP (4), pharmacists should know medications with 
pharmacogenomics implications, the associated tests and their interpretations as well as 
recommended therapeutic modifications for genetically “high-risk” individuals. To this end, we 
asked the final year student pharmacists if they knew at least ten medications that the FDA either 
requires or recommends pharmacogenomics testing prior to use (Table 3). Only 32% (n=108) 
responded affirmatively while 44% (n=150) did not know at least ten of such medications. 
Furthermore, when queried on their ability to recommend the appropriate pharmacogenomics 
tests for the medications that require it, only 21% (n=72) stated they could and about a third 
(27%, n=91)) reported having the ability to accurately interpret pharmacogenomics tests.  Again, 
32% (n=107) felt knowledgeable to recommend alternative therapies and/or dose changes based 
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on pharmacogenomic results.. Lastly, 62% (n=209) were not aware of the Clinical 
Pharmacogenetics Implementation Consortium’s (CPIC) guidelines which provide a clinical 
recommendations to clinicians on how to use genetic information to guide medication selection 
and dosing.(15)  
As expected, the students’ past exposure to pharmacogenomics content in their curricula 
was strongly associated with increased agreement with the statements about readiness to use 
pharmacogenomics in practice (Figure 3). More exposure to pharmacogenomics was correlated 
with the students’ knowledge of  at least ten medications needing pharmacogenomic testing 
(β=0.349, 95% CI: 0.231-0.468); their ability to recommend appropriate pharmacogenomic tests 
for such medications (β=0.251, 95% CI: 0.128-0.375); their ability to accurately interpret these 
tests (β=0.363, 95% CI: 0.244-0.482); their knowledge of  the appropriate therapeutic 
recommendations based on the pharmacogenomics test results (β =0.342, 95% CI: 0.237-0.448); 
and their awareness of CPIC guidelines (β=0.313, 95% CI: 0.206-0.420).  
 
Discussion: 
Clinical applications of pharmacogenomics are increasingly gaining acceptance as 
evidenced by the National Institutes of Health National Human Genome Research Institute 
(NIH/NHGRI) – funded consortia focused on developing tools and clinical implementation 
strategies (16-18) and the availability of databases such as the FDA Table of Biomarkers(19) and 
the Pharmacogenomics Knowledge Base: www.pharmgkb.org(20).  
Pharmacists are distinctively qualified medical professionals to lead translational 
pharmacogenomics and assume essential roles in its education and sustained adoption in 
professional curricula (3). Of the 339 participants in this study, 82% had been exposed to 
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pharmacogenomics content in varying degrees throughout their pharmacy school program 
ranging from 1 – 3 lectures to several weeks of pharmacogenomics APPE rotation experience. 
This finding sadly affirms the 2010 study by Murphy et al., in which 67 (89%) colleges/schools 
of pharmacy reported having pharmacogenomics content in their doctor of pharmacy curricula 
albeit the dedicated didactic hours differed greatly from school to school (11). In that study, 28 
schools (41%) dedicated 10 or fewer hours, while 29 (42%) reported 11 to 30 didactic hours for 
pharmacogenomics. A decade later, Murphy et al.’s findings still resonate as demonstrated in the 
present study. Almost half of the final year students in our survey (46%) encountered 
pharmacogenomics content in 1 – 3 lectures, and approximately 12% received no 
pharmacogenomics instruction throughout their pharmacy school tutelage. In all,  40% noted that 
pharmacogenomics has been a relevant part of their pharmacy training. This is almost a four-fold 
boost from the 2011 finding by McCullough and colleagues in which only 10% of surveyed 
pharmacists stated that pharmacogenomics had been a relevant component of their pharmacy 
education(5). 
From this study and others, it is clear pharmacists believe that pharmacogenomics is a 
relevant tool to optimize patient care however, majority are not comfortable in their abilities to 
utilize it in their practice (5, 6, 14, 21). The current study and others also confirm that 
educational opportunities available to student pharmacists in their training may not be sufficient 
to resolve this issue. Seventy-one percent of the students’ believe that it should be covered in 
detail in pharmacy curricula; 52% state that pharmacists should be required to have substantial 
knowledge in pharmacogenomics prior to graduation; and 56% intend to continue seeking 
educational opportunities in this discipline post-graduation.  Clearly, a great number of the 
students want this information. 
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There are two main reasons for the inadequate training in pharmacogenomics.  The first 
is the lack of well-trained educators to introduce content that addresses core competencies. In our 
study, 25% of the faculty members were formally trained in pharmacogenomics while the others 
completed coursework, certificate programs and were exposed through involvement in 
pharmacogenomics research (Table 2). Although a few were clinical faculty, none is actively 
practicing in pharmacogenomics.  
University of California San Diego Pharmacogenomics Education Program 
(PharmGenEd) (22), University of Pittsburgh’s Test2Learn(23), University of Florida (UF) 
Health Personalized Medicine Program graduate and certificate training program (24)  and the 
University of Colorado Pharmacogenomics Certificate Program (25) are all excellent 
opportunities for pharmacy school faculty to receive hands-on training in pharmacogenomics 
either in person or virtually. Some programs provide a shared curriculum that may be adopted in 
various schools and some use the train-the-trainer methods to provide the best results. In all, 
these avenues were designed for educators and practitioners who are interested in using 
pharmacogenomic information in their practice to educate the next generation or optimize patient 
outcomes respectively. The leadership of colleges of pharmacy should invest in their faculty to 
participate in these programs especially those who are in charge of providing the didactic 
lectures on pharmacogenomics. Moreover, faculty members in this position should be aware of 
the newly updated pharmacogenomics core competencies in pharmacy practice (26) and 
resources(15, 20) to better instruct their students in the likely event that they encounter examples 
that may not have been covered in their courses. Of note, CPIC guidelines were unknown to 62% 
of the respondents in our study which highlights the need for CPIC and other pharmacogenomics 
resource leaders to consider expanding their reach beyond practicing clinicians to trainees. 
 14 
Another proposed strategy for overcoming this challenge is to incorporate pharmacogenomics 
exposure early in the Pharm.D curriculum through the foundational courses and into practice-
based therapeutic courses, Introductory Pharmacy Practice Experiences (IPPE) and APPEs.(27) 
In addition to the learning objectives in Table 2, other training content to be considered include 
but not limited to online resources(28), utilization of electronic health records in 
pharmacogenomics, potential implications with over-the-counter medications and herbal 
therapies,  reimbursement, and ethical, legal and social issues. 
The second challenge is the lack of experiential and practice-based opportunities to 
engage the students in real-life applications of pharmacogenomics. Formea and colleagues 
reported marginal retention of educational objectives among practicing pharmacists after two 
months of providing a fundamental pharmacogenomics education program accredited by ACPE 
for continued education (29). They concluded that education in this topic area will require more 
effort to increase knowledge and comfort in dealing with its clinical applications  as 
demonstrated by Galvez-Peralta and colleagues  in the School of Pharmacy in West Virginia 
University(30). . Our findings support this statement and demonstrate that the extent of 
pharmacogenomics educational exposure and use of practice-based scenarios for teaching may 
play an important role in preparing the students for the practice setting (31). Final year students 
who were enrolled in pharmacogenomics APPE rotations were more likely to be prepared to 
apply pharmacogenomics knowledge in practice than those from the other training methods 
(Figure 3). To the best of our knowledge, there are two pharmacogenomics APPE rotation 
opportunities in the New York / New Jersey region; at Mount Sinai (32) and Touro College of 
Pharmacy; and a handful of others across the country with very limited openings for students 
annually. Mount Sinai offers an elective rotation to final year student pharmacists from two New 
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York schools as well as post-graduate year one (PGY1) and post-graduate year two (PGY2) 
pharmacy residents in the Mount Sinai Health System. Of note, it is a required rotation for PGY2 
oncology pharmacy residents at The Mount Sinai Hospital. This training is a combination of 
topic and patient case discussions, development of clinical decision support content and 
stakeholder educational tools and personal genotyping.  Furthermore, the ASHP Online 
Residency Directory (https://accred.ashp.org/aps/pages/directory/residencyProgramSearch.aspx) 
lists three accredited PGY2 clinical pharmacogenomics residencies. With approximately fifteen 
thousand new graduates annually (33), the training spots identified here are not nearly enough to 
accommodate the need. School leaderships should make every effort to hire newly trained 
pharmacogenomics experts into positions that provide both the didactic and the experiential 
examples for students. Although, establishing  a specialty pharmacogenomics residency is not 
feasible at most institutions, partnering with health systems that are implementing 
pharmacogenomics(32, 34, 35) and assigning faculty liaisons and/or designing student rotation 
opportunities may be possible and should be considered.  
 Furthermore, the strength of the relationship observed between the exposure to 
pharmacogenomics content and perceived readiness to apply in practice may be limited by the 
subjective nature of the survey. Also, this project is not in a position to accurately assess whether 
the responses provided are an accurate representation of the students’ knowledge. Future studies 
should focus on objective knowledge-based assessments to address this concern. Moreover, the 
response rate per school ranged from 16% to 65% which demonstrates that the results may not be 
fully representative of all final year pharmacy students in this region. Also, the findings may not 
be applicable to all students in the United States especially for those students who have advanced 
training options at their institutions.  
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Conclusion 
 In all, final year student pharmacists reported varying exposure to pharmacogenomics 
content in their pharmacy training; had positive attitudes towards the clinical relevance of the 
discipline; yet they expressed low confidence in their readiness to utilize this information in 
practice. Hence, practice-based training opportunities taught by well-trained faculty may be 
needed to prepare our future pharmacists in this discipline. 
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Key Points  
1. Final year student pharmacists had positive attitudes and perceptions towards 
pharmacogenomics and its clinical relevance even though majority was not ready to 
implement related concepts in practice. 
2.  Student pharmacists were more likely to feel confident in their ability to use 
pharmacogenomics in practice after enrolling in pharmacogenomics APPE rotations.  
3. Schools of pharmacy should invest in practice-based training opportunities taught by 
well-trained faculty to increase readiness to implement related concepts in practice. 
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Tables and Figures 
 
Table 1: Demographics Information for the Final Year Pharmacy Student Respondents.  
  
P4 Students (n = 339) N (%) 
Gender  
Female 213 (62.8) 
Male 123 (36.3) 
Prefer not to disclose 3 (0.90) 
Age Range  
Less than 21 years 1 (0.30) 
21 - 25 years 194 (57.2) 
26 - 30 years 106 (31.3) 
31 - 40 years 33 (9.70) 
over 40 years 4 (1.20) 
no response 1 (0.30) 
Highest level of education before pharmacy School 
High School Diploma 147 (43.4) 
Bachelor's degree 127 (37.5) 
Master's degree 11 (3.20) 
Doctorate / JD 31 (9.10) 
Other 22 (6.50) 
No response 1 (0.30) 
Post Graduate Plans  
Residency 83 (24.5) 
Fellowship 19 (5.60) 
Community  158 (46.6) 
Hospital 32 (9.40) 
Undecided 47 (13.9) 
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Table 2: Description of Participating Schools of Pharmacy and their Pharmacogenomics Educational Opportunities. 
 
 
 
 
 
 
School A School B School C School D School E School F School G School H
64.60% 53.10% 11.70% 26.90% 27.20% 57% 16.20% 39.40%
Terminal Degree PhD PhD PhD and clinical PharmD Clinical PharmD PhD RPh and PhD PhD PhD
Formal PGx Training NO NO NO NO NO YES YES NO
Other PGx-related Training?
PGx coursework as part 
of a Pharmacology Ph.D.
Applied PGx research as an 
industry senior scientist 
position PGx certificate program NO
Molecular and 
epigenetics
PGx Post-Doc 
Fellowship
PGx PhD and Post-Doc 
Fellowship in PGx
involved in PGx 
research in the past
standalone or integrated? Stand-alone Stand-alone BOTH Integrated Integrated Stand-alone BOTH Stand-alone
If integrated, what course? N/A N/A Pharmacokinetics (2 lectures) Pharmacotherapy Pharmacology N/A Several courses N/A
If standalone, is it required or an elective? Elective Required Elective N/A N/A Required Required Required
Average student per year for the elective 
courses 35 N/A 10 to 15 N/A N/A N/A N/A N/A
When is the course offered?
1st, 2nd, or 3rd 
professional year
2nd professional year 3rd professional year
2nd or 3rd 
professional year
2nd professional 
year
3rd professional year 3rd professional year 2nd professional year
Length of course/credits
one semeste; 2 credit 
hours one semester; 2 credit hours one semester; 2 credit hours N/A N/A
one semester; 2 
credits
one semester; 2 
credits
one semester; 2 
credits
To identify medications that require or are 
recommended by the FDA to have PGx 
testing. YES YES YES N/A YES N/A YES YES
To recommend appropriate PGx tests for the 
medications that require testing. YES YES YES N/A NO NO YES NO
To accurately interpret pharmacogenomics 
tests. YES YES YES N/A NO NO YES NO
To recommend alternative therapies or doses 
when required by a PGx test result. YES YES YES N/A YES YES YES YES
Become familiar with how to access, 
interpret and utilize the CPIC guidelines. YES NO YES N/A NO N/A YES NO
PGx APPE Opportunity NO YES NO YES YES NO NO NO
Length of APPE N/A 5 weeks N/A 5 weeks 6 weeks N/A N/A N/A
PGx Didactic 
Course 
Details
PGx APPE**
** The PGx APPE training addresses all the learning objectives listed. 
PGx Faculty 
PGx Course 
** Learning 
Objectives
Survey Response Rate:
School/College of Pharmacy
 1 
 
 
Table 3: Survey responses from the final year pharmacy students 
 
  Number of Respondents (%) 
Survey Questions 
Strongly 
Agree / Agree Neutral 
Strongly Disagree 
/ Disagree 
No 
response 
Perception 
of the 
clinical 
relevance 
of PGx 
Pharmacogenomics is an integral part 
of the pharmacy profession. 
214 (63.1) 67 (19.8) 28 (8.26) 30 (8.85) 
Pharmacogenomics may be an integral 
part of my practice as a pharmacist. 
205 (60.5) 62 (18.3) 42 (12.4) 30 (8.85) 
I may encounter pharmacogenomics 
related questions during my practice as 
a pharmacist. 
234 (69.0) 45 (13.3) 29 (8.55) 31 (9.14) 
Pharmacogenomics is a useful tool that 
pharmacists and medical professionals 
can use to optimize medication efficacy 
and/or prevent adverse events. 
273 (80.5) 27 (7.96) 9 (2.65) 30 (8.85) 
Attitudes 
towards 
PGx 
education 
Pharmacogenomics has been a 
relevant part of my doctor of pharmacy 
curriculum. 
136 (40.1) 88 (26.0) 96 (28.3) 19 (5.60) 
Pharmacogenomics should be covered 
in detail for all colleges and schools of 
pharmacy. 
239 (70.5) 67 (19.8) 13 (3.83) 20 (6.00) 
Final year (P4) pharmacy students 
should be required to have substantial 
knowledge of pharmacogenomics prior 
to graduation. 
175 (51.6) 97 (28.6) 48 (14.2) 19 (5.60) 
Post-graduation, I intend to read up on 
pharmacogenomics especially on how 
it influences my practice and /or 
specialty. 
188 (55.5) 81 (23.9) 51 (15.0) 19 (5.60) 
Readiness 
to use PGx 
knowledge 
in practice 
I know at least ten medications that 
require or are recommended to have 
pharmacogenomics testing as per the 
FDA. 
108 (31.9) 55 (16.2) 150 (44.2) 26 (7.67) 
I am able to recommend the 
appropriate pharmacogenomics test/s 
for the medications that require it. 
72 (21.2) 79 (23.3) 161 (47.5) 27 (7.96) 
I am able to accurately interpret 
pharmacogenomics tests. 
91 (26.8) 75 (22.1) 147 (43.4) 26 (7.67) 
Based on the results of a 
pharmacogenomics test, I am able to 
recommend alternative therapies or 
dose changes when required.  
107 (31.6) 82 (24.2) 124 (36.6) 26 (7.67) 
I am aware of the Clinical 
Pharmacogenetics Implementation 
Consortium's (CPIC) guidelines on how 
to use genetic information to guide 
drug therapy selection/dosing. 
55 (16.2) 48 (14.2) 209 (61.7) 27 (7.96) 
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Figure 1: The extent of pharmacogenomics education achieved by the final year student 
pharmacists at the time of this survey.   
 
Figure 1 Legend: Percentages were calculated from the "previous exposure to 
pharmacogenomics demographic question”. Those who did not answer were excluded from the 
ordered categorical variable constructed from these responses. Due to the low number of 
respondents who endorsed having genetics major or minor previously (2), that category was also 
excluded”. 
 
 
 
 
 
 
 2 
Figure 2: Relationship between exposure to pharmacogenomics education and final year 
student pharmacists' attitudes towards pharmacogenomics education.  
 
Figure 2 Legend:  The effects of exposure to previous pharmacogenomics education on attitudes 
towards pharmacogenomics education are displayed as ß values, with 95% confidence intervals 
displayed as error bars. The measure of pharmacogenomics training was significantly 
associated with more agreement to three of the four questions assessing attitudes towards 
pharmacogenomics education: pharmacogenomics had been a relevant part of their curriculum 
(Standardized Beta (ß) =0.365, 95% Confidence Interval (CI): 0.252 - 0.477); final year 
pharmacy students should be required to have substantial pharmacogenomics knowledge (ß 
=0.150, 95% CI: 0.0.039 - 0.260); and I intend to read up on pharmacogenomics after 
graduating (ß =0.116, 95% CI: 0.003 - 0.229). It was also suggestively associated with the 
fourth question, on agreement that it should be covered in detail in all pharmacy schools (ß 
=0.129, 95% CI: -0.005 - 0.262). 
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Figure 3: The relationship between exposure to pharmacogenomics education and 
readiness to use it in practice. 
 
Figure 3 Legend: Different levels of exposure to pharmacogenomics education are categorized 
along the x-axis, and a mean score of PGx readiness by group is displayed on the y-axis, with 
error bars corresponding to the standard errors within each group. The score was calculated for 
each person by treating agreement with each of the five readiness statements as 1, and 
disagreement as -1 (neutral is treated as 0) and summing all five together. The correlation 
between level of pharmacogenomics education exposure and readiness score was 0.389 (95% 
Confidence Interval: 0.291 - 0.478; R2 = 0.151), suggesting a positive relationship between 
more exposure to pharmacogenomics education and increased readiness to use 
pharmacogenomics in practice. 
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